8 completed, 6 active not recruiting, 5 not yet recruiting, 5 recruiting. 14 Phase 2, 8 Phase 1, 4 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Chronic Myeloid Leukemia (CML): new trials by email Literature Review of Chronic Myeloid Leukemia (CML) trials Research Report on Chronic Myeloid Leukemia (CML)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| Study of CD38 and CD56 in Chronic Myeloid Leukemia cd 38 and cd 56 - Chronic Myeloid Leukemia (CML) | Not yet recruiting | Sohag University | 200 | 2026-09-01 | 2026-08-05 | |
| ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. - Myeloproliferative Disease, Polycythemia Vera | Not applicable | Not yet recruiting | Carmen Fava | 25 | 2026-08-01 | 2026-04-09 |
| TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Stanford University | 50 | 2026-07-21 | 2026-08-17 |
| Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations asciminib 200 mg BID - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Thomas Ernst, PD Dr. med. | 50 | 2026-06-22 | 2026-08-27 |
| Identification of BCR::ABL1 Mutations by Digital PCR in CML Peripheral blood withdrawal for BCR::ABL1 mutations testing - Chronic Myeloid Leukemia (CML) | Not applicable | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 150 | 2026-02-01 | 2025-09-05 |
| Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy Imatinib, Artesunate - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Obafemi Awolowo University | 75 | 2025-07-01 | 2026-10-14 |
| Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid Leukemia Chronic Myeloid Leukemia (CML) | Not yet recruiting | Assiut University | 50 | 2025-05-01 | 2025-03-07 | |
| Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network Chronic Myeloid Leukemia (CML) | Recruiting | University of Milano Bicocca | 2000 | 2025-04-17 | 2025-09-10 | |
| Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. ABL001/Asciminib - Chronic Myeloid Leukemia (CML) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 20 | 2025-02-18 | 2026-04-21 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece A manualised post-traumatic growth intervention for people with hematological cancers - Blood Cancers, Leukemia | Not applicable | Active not recruiting | University of West Attica | 80 | 2024-06-06 | 2026-09-10 |
| Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial Imatinib (STI571) - Chronic Myeloid Leukemia (CML) | Enrolling by invitation | Poitiers University Hospital | 787 | 2024-05-01 | 2024-10-17 | |
| Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia Ponatinib 15mg QD, Ponatinib 30mg QD - Chronic Myeloid Leukemia (CML) | Phase 2 | Unknown | Associazione Italiana Pazienti Leucemia Mieloide Cronica | 50 | 2021-02-01 | 2021-02-03 |
| Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality Optimal medical treatment, usual clinical practice - Chronic Myeloid Leukemia (CML) | Phase 3 | Terminated | University Hospital, Angers | 80 | 2019-12-20 | 2025-03-17 |
| The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans [14C] HQP1351 - Chronic Myeloid Leukemia (CML) | Phase 1 | Completed | Ascentage Pharma Group Inc. | 6 | 2019-11-19 | 2021-09-08 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Cyclophosphamide, Fludarabine, Thiotepa - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 69 | 2019-01-31 | 2026-09-15 |
| Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide - Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 9 | 2018-07-25 | 2025-04-06 |
| EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors Collection of blood and bone marrow - Chronic Myeloid Leukemia (CML), Chronic Phase | Not applicable | Unknown | University Hospital, Clermont-Ferrand | 160 | 2018-02-01 | 2024-04-09 |
| Second STOP After Pioglitazone Priming in CML Patients Pioglitazone + TKI - Chronic Myeloid Leukemia (CML) | Phase 2 | Recruiting | Versailles Hospital | 26 | 2016-12-01 | 2026-07-06 |
Showing 20 of 33. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (33) · Leukemia, Myeloid, Acute (8) · Myelodysplastic Syndromes (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia (5) · Lymphoma, Non-Hodgkin (4) · Hodgkin Disease (3) · Leukemia, Myelomonocytic, Juvenile (3) · Lymphoma (3) · Myeloproliferative Disorders (3) · Hematologic Diseases (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid (2) · Multiple Myeloma (2)
Chronic Disease (33) · Disease Attributes (33) · Hemic and Lymphatic Diseases (33) · Pathologic Processes (33) · Pathological Conditions, Signs and Symptoms (33) · Bone Marrow Diseases (32) · Neoplasms by Histologic Type (32) · Hematologic Diseases (31) · Leukemia, Myeloid (31) · Neoplasms (31) · Myeloproliferative Disorders (30) · Leukemia (28) · Immune System Diseases (10) · Immunoproliferative Disorders (9) · Leukemia, Lymphoid (9)
Cyclophosphamide (5) · Melphalan (5) · Imatinib Mesylate (4) · Thiotepa (4) · fludarabine (4) · fludarabine phosphate (4) · Filgrastim (3) · Mesna (3) · Tacrolimus (3) · ponatinib (3) · Busulfan (2) · Dasatinib (2) · Granulocyte Colony-Stimulating Factor (2) · Rituximab (2) · asciminib (2)
Novartis Pharmaceuticals (4) · National Heart, Lung, and Blood Institute (NHLBI) (3) · Ariad Pharmaceuticals (2) · Bristol-Myers Squibb (2) · St. Jude Children's Research Hospital (2) · University Hospital, Clermont-Ferrand (2) · Ascentage Pharma Group Inc. (1) · Assiut University (1) · Associazione Italiana Pazienti Leucemia Mieloide Cronica (1) · Carmen Fava (1) · Diane George (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Memorial Sloan Kettering Cancer Center (1) · Obafemi Awolowo University (1) · Ossium Health, Inc. (1)
United States (11) · France (6) · Italy (3) · Germany (2) · Brazil (1) · China (1) · Greece (1) · Japan (1) · Nigeria (1) · Russia (1) · South Korea (1)
Brandon Triplett, MD (2) · Brian Shaffer, MD (1) · Carlo Gambacorti (1) · Carmen Fava (1) · Diane George, MD (1) · Dr. B. A. Adeagbo (1) · Feng Shao, Doctor (1) · John Barrett, MD (1) · Minocher Battiwalla, MD (1)
PMID 21134985, PMID 22198310, PMID 28444644, PMID 34699069, PMID 36040480, PMID 37964424
2018 (1), 2025 (1)